195.22
price up icon3.28%   6.20
 
loading
前日終値:
$189.02
開ける:
$189.92
24時間の取引高:
8.08M
Relative Volume:
1.28
時価総額:
$344.84B
収益:
$58.33B
当期純損益:
$3.76B
株価収益率:
92.96
EPS:
2.1
ネットキャッシュフロー:
$15.39B
1週間 パフォーマンス:
+2.60%
1か月 パフォーマンス:
+2.75%
6か月 パフォーマンス:
+6.16%
1年 パフォーマンス:
+2.90%
1日の値動き範囲:
Value
$189.78
$197.06
1週間の範囲:
Value
$187.62
$198.83
52週間の値動き範囲:
Value
$163.81
$218.66

Abbvie Inc Stock (ABBV) Company Profile

Name
名前
Abbvie Inc
Name
セクター
Healthcare (1164)
Name
電話
(847) 932-7900
Name
住所
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
職員
55,000
Name
Twitter
@abbvie
Name
次回の収益日
2025-04-25
Name
最新のSEC提出書
Name
ABBV's Discussions on Twitter

ABBV を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
ABBV
Abbvie Inc
195.22 333.89B 58.33B 3.76B 15.39B 2.10
Drug Manufacturers - General icon
LLY
Lilly Eli Co
762.33 664.39B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
167.33 396.75B 90.63B 22.66B 16.40B 9.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
115.30 220.18B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
MRK
Merck Co Inc
79.29 196.16B 63.62B 16.41B 17.04B 6.49

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-05-14 ダウングレード Citigroup Buy → Neutral
2025-04-22 開始されました Cantor Fitzgerald Overweight
2024-12-10 再開されました BofA Securities Neutral
2024-12-05 ダウングレード Daiwa Securities Outperform → Neutral
2024-11-22 アップグレード Leerink Partners Market Perform → Outperform
2024-11-15 開始されました Wolfe Research Outperform
2024-11-04 アップグレード Argus Hold → Buy
2024-10-17 開始されました Bernstein Mkt Perform
2024-06-05 アップグレード HSBC Securities Hold → Buy
2024-05-17 開始されました Cantor Fitzgerald Overweight
2024-01-29 アップグレード William Blair Mkt Perform → Outperform
2023-12-18 ダウングレード HSBC Securities Buy → Hold
2023-12-11 アップグレード Goldman Neutral → Buy
2023-11-09 開始されました Deutsche Bank Hold
2023-10-30 アップグレード Barclays Equal Weight → Overweight
2023-10-20 再開されました UBS Neutral
2023-09-29 開始されました Raymond James Outperform
2023-07-25 開始されました William Blair Mkt Perform
2023-07-14 開始されました HSBC Securities Buy
2023-04-05 ダウングレード Argus Buy → Hold
2023-03-01 開始されました Guggenheim Buy
2023-02-22 ダウングレード Wolfe Research Outperform → Peer Perform
2023-02-10 アップグレード SVB Securities Underperform → Market Perform
2022-11-18 開始されました Credit Suisse Outperform
2022-11-08 ダウングレード Societe Generale Buy → Hold
2022-08-01 ダウングレード Atlantic Equities Overweight → Neutral
2022-05-23 開始されました SVB Leerink Underperform
2022-05-06 ダウングレード Daiwa Securities Outperform → Neutral
2022-04-06 再開されました Morgan Stanley Overweight
2022-02-28 ダウングレード UBS Buy → Neutral
2022-02-03 繰り返されました BMO Capital Markets Outperform
2022-02-03 繰り返されました Barclays Equal Weight
2022-02-03 繰り返されました BofA Securities Neutral
2022-02-03 繰り返されました Goldman Neutral
2022-01-13 開始されました Redburn Buy
2022-01-12 繰り返されました BMO Capital Markets Outperform
2021-12-09 再開されました Wells Fargo Overweight
2021-11-23 アップグレード Societe Generale Hold → Buy
2021-07-27 再開されました Truist Buy
2021-04-07 再開されました RBC Capital Mkts Outperform
2020-11-10 再開されました Bernstein Outperform
2020-09-29 開始されました Berenberg Hold
2020-06-23 アップグレード Atlantic Equities Neutral → Overweight
2020-06-09 アップグレード Wolfe Research Peer Perform → Outperform
2020-06-02 アップグレード Argus Hold → Buy
2020-05-18 再開されました BofA/Merrill Neutral
2020-05-12 アップグレード JP Morgan Neutral → Overweight
2020-05-11 再開されました Morgan Stanley Overweight
2020-04-20 アップグレード RBC Capital Mkts Sector Perform → Outperform
2020-03-23 ダウングレード Societe Generale Buy → Hold
2020-02-27 開始されました Barclays Equal Weight
2020-02-06 開始されました Mizuho Buy
2020-01-07 開始されました RBC Capital Mkts Sector Perform
2019-12-26 繰り返されました Cowen Outperform
2019-09-26 アップグレード Citigroup Neutral → Buy
2019-08-20 アップグレード Piper Jaffray Neutral → Overweight
2019-06-27 アップグレード Wolfe Research Underperform → Peer Perform
2019-06-26 アップグレード SVB Leerink Mkt Perform → Outperform
2019-05-28 開始されました Goldman Neutral
2019-04-29 アップグレード BMO Capital Markets Underperform → Market Perform
すべてを表示

Abbvie Inc (ABBV) 最新ニュース

pulisher
09:02 AM

If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today - The Globe and Mail

09:02 AM
pulisher
12:27 PM

AbbVie reports encouraging data from Upadacitinib trial for alopecia areata - MSN

12:27 PM
pulisher
Aug 02, 2025

AbbVie's Q2 2025 Earnings Call: Unpacking Contradictions in Skyrizi Growth, Inventory Strategies, and Market Dynamics - AInvest

Aug 02, 2025
pulisher
Aug 02, 2025

AbbVie Shines in Earnings Call with Strong Growth - The Globe and Mail

Aug 02, 2025
pulisher
Aug 02, 2025

Key deals this week: Chart Industries, Northwind Midstream, AbbVie, Palo Alto Networks and more - Seeking Alpha

Aug 02, 2025
pulisher
Aug 02, 2025

AbbVie’s Real-World Study on Parkinson’s Treatment: A Potential Game Changer - The Globe and Mail

Aug 02, 2025
pulisher
Aug 02, 2025

AbbVie Reports Strong Q2 2025 Financial Results - The Globe and Mail

Aug 02, 2025
pulisher
Aug 01, 2025

AbbVie Shares Surge 3.28% on Strong Q2 Results and Analyst Upgrades, Trading Volume Ranks in Top 500 by Daily Trading Volume - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

Why AbbVie Stock Flew Higher on Friday - Nasdaq

Aug 01, 2025
pulisher
Aug 01, 2025

Major pharma company takes on Oregon 340B drug law - The Business Journals

Aug 01, 2025
pulisher
Aug 01, 2025

Why Is AbbVie Stock Gaining Friday?AbbVie (NYSE:ABBV) - Benzinga

Aug 01, 2025
pulisher
Aug 01, 2025

Deal Dispatch: MEG Bidding War Heats Up, L Catterton Takes Bite Out Of Kisshokichi, Sunnova's Still Shining - Benzinga

Aug 01, 2025
pulisher
Aug 01, 2025

Why AbbVie (ABBV) Stock Is Up Today - Yahoo Finance

Aug 01, 2025
pulisher
Aug 01, 2025

AbbVie’s New Study on CLL Treatment: A Potential Game Changer? - The Globe and Mail

Aug 01, 2025
pulisher
Aug 01, 2025

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and AbbVie (ABBV) - The Globe and Mail

Aug 01, 2025
pulisher
Aug 01, 2025

AbbVie Inc. (NYSE:ABBV) Q2 2025 Earnings Call Transcript - MSN

Aug 01, 2025
pulisher
Aug 01, 2025

AbbVie Inc (ABBV) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... - Yahoo Finance

Aug 01, 2025
pulisher
Aug 01, 2025

Stock Analysis | Abbvie OutlookA Mixed Technical Picture Amid Divergent Analyst Ratings - AInvest

Aug 01, 2025
pulisher
Jul 31, 2025

AbbVie's Stock Dips 0.15% as Trading Volume Surges 108.9% to Rank 50th in Market Activity Behind Strong Q2 Earnings - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

M&A News: AbbVie Eyes $1B Acquisition of Gilgamesh Therapeutics - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie Stock Pops After Earnings Beat and Guidance Raised - MSN

Jul 31, 2025
pulisher
Jul 31, 2025

Why AbbVie Stock Slumped Today - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

Market Today: Meta and Microsoft Lead AI Surge, AbbVie Eyes Acquisition - GuruFocus

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength - insights.citeline.com

Jul 31, 2025
pulisher
Jul 31, 2025

In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A - BioPharma Dive

Jul 31, 2025
pulisher
Jul 31, 2025

Research Alert: CFRA Retains Buy Opinion On Shares Of Abbvie Inc. - 富途牛牛

Jul 31, 2025
pulisher
Jul 31, 2025

CoreWeave, Arm Holdings, AbbVie: Trending Tickers - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie Earnings: Continued Impressive Demand for Skyrizi, Neuroscience Portfolio Support Growth - Morningstar

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie: Q2 Earnings Snapshot - The Washington Post

Jul 31, 2025
pulisher
Jul 31, 2025

Trump demands largest pharma companies slash US drug prices - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie Stock Eyes Breakout as Pipeline and Profits Grow - MarketBeat

Jul 31, 2025
pulisher
Jul 31, 2025

Earnings call transcript: AbbVie Q2 2025 sees stock surge on earnings beat - Investing.com Canada

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie sees no outsized tariff exposure, boosts profit forecast - Reuters

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie Lifts Forecasts As Immunology Drugs Drive Growth - Finimize

Jul 31, 2025
pulisher
Jul 31, 2025

Psychedelic stocks up after report on AbbVie-Gilgamesh deal talks - Seeking Alpha

Jul 31, 2025
pulisher
Jul 31, 2025

Arm Holdings slips on guidance, AbbVie Q2 beat, Bristol-Myers outlook - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie’s Real-World Study on Parkinson’s Treatment: A Potential Game Changer? - The Globe and Mail

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie Stock Pops After Earnings. What’s Driving Shares Higher. - Barron's

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie raises guidance as key drugs and pipeline deals boost growth - Crain's Chicago Business

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie 2nd-quarter beats expectations - The Pharma Letter

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal - Bloomberg

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie lifts profit forecast on strong demand for newer immunology drugs - Reuters

Jul 31, 2025
pulisher
Jul 31, 2025

Sales of Skyrizi, Rinvoq Help AbbVie Results Top Wall Street’s Forecasts - The Wall Street Journal

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates - Yahoo.co

Jul 31, 2025
pulisher
Jul 31, 2025

Is Now the Time to Buy AbbVie Ahead of a Pivotal Transition? - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie raises full-year earnings guidance amid acquisition drive - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie lifts guidance despite slump in Humira sales - MSN

Jul 31, 2025

Abbvie Inc (ABBV) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general JNJ
$167.33
price up icon 1.57%
drug_manufacturers_general NVS
$115.30
price up icon 1.37%
drug_manufacturers_general MRK
$79.29
price up icon 1.50%
drug_manufacturers_general NVO
$48.19
price up icon 2.38%
$296.88
price up icon 0.60%
大文字化:     |  ボリューム (24 時間):